Medistim Croissance future

Future contrôle des critères 2/6

Medistim devrait augmenter ses bénéfices et ses revenus de 4.1% et de 3.2% par an respectivement, tandis que le BPA devrait croître de croître de 4.1% par an.

Informations clés

4.1%

Taux de croissance des bénéfices

4.1%

Taux de croissance du BPA

Medical Equipment croissance des bénéfices	18.8%
Taux de croissance des recettes	3.2%
Rendement futur des capitaux propres	n/a
Couverture par les analystes	Low
Dernière mise à jour	26 Oct 2024

Mises à jour récentes de la croissance future

Medistim ASA Just Missed Earnings - But Analysts Have Updated Their Models

Oct 28

Medistim ASA Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Aug 19

Medistim ASA Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Mar 04

Recent updates

Medistim ASA Just Missed Earnings - But Analysts Have Updated Their Models

Oct 28

Medistim ASA Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Aug 19

Medistim ASA Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Mar 04

Is Medistim ASA's(OB:MEDI) Recent Stock Performance Tethered To Its Strong Fundamentals?

Mar 19

Medistim ASA (OB:MEDI) Just Reported And Analysts Have Been Lifting Their Price Targets

Mar 02

Here's What You Should Know About Medistim ASA's (OB:MEDI) 1.1% Dividend Yield

Feb 19

A Look Into Medistim's (OB:MEDI) Impressive Returns On Capital

Jan 21

Have Insiders Been Selling Medistim ASA (OB:MEDI) Shares?

Dec 27

Medistim (OB:MEDI) Has Rewarded Shareholders With An Exceptional 375% Total Return On Their Investment

Dec 10

Could The Market Be Wrong About Medistim ASA (OB:MEDI) Given Its Attractive Financial Prospects?

Nov 23

Prévisions de croissance des bénéfices et des revenus

OB:MEDI - Estimations futures des analystes et données financières antérieures (NOK Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	583	114	N/A	N/A	1
12/31/2025	561	110	101	116	1
12/31/2024	547	109	105	135	1
9/30/2024	542	102	87	117	N/A
6/30/2024	533	104	99	128	N/A
3/31/2024	526	103	105	135	N/A
12/31/2023	521	104	83	113	N/A
9/30/2023	527	117	86	107	N/A
6/30/2023	519	116	74	96	N/A
3/31/2023	499	116	71	92	N/A
12/31/2022	486	114	92	113	N/A
9/30/2022	459	98	115	127	N/A
6/30/2022	444	92	126	138	N/A
3/31/2022	431	93	120	132	N/A
12/31/2021	418	91	116	127	N/A
9/30/2021	397	88	90	101	N/A
6/30/2021	378	84	63	73	N/A
3/31/2021	356	70	59	70	N/A
12/31/2020	356	69	63	74	N/A
9/30/2020	358	71	68	82	N/A
6/30/2020	360	74	78	91	N/A
3/31/2020	371	75	78	92	N/A
12/31/2019	357	70	67	80	N/A
9/30/2019	363	79	62	78	N/A
6/30/2019	355	73	58	74	N/A
3/31/2019	338	64	44	60	N/A
12/31/2018	323	57	39	56	N/A
9/30/2018	305	46	53	67	N/A
6/30/2018	303	48	N/A	61	N/A
3/31/2018	296	45	N/A	54	N/A
12/31/2017	296	48	N/A	62	N/A
9/30/2017	281	41	N/A	41	N/A
6/30/2017	274	39	N/A	36	N/A
3/31/2017	272	41	N/A	45	N/A
12/31/2016	263	39	N/A	30	N/A
9/30/2016	274	45	N/A	35	N/A
6/30/2016	268	45	N/A	37	N/A
3/31/2016	258	43	N/A	38	N/A
12/31/2015	250	40	N/A	45	N/A
9/30/2015	242	39	N/A	47	N/A
6/30/2015	233	37	N/A	48	N/A
3/31/2015	223	33	N/A	51	N/A
12/31/2014	214	31	N/A	49	N/A
9/30/2014	200	28	N/A	37	N/A
6/30/2014	193	24	N/A	37	N/A
3/31/2014	194	26	N/A	27	N/A
12/31/2013	190	27	N/A	26	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de MEDI ( 4.1% par an) est supérieure au taux d'épargne ( 2.4% ).

Bénéfices vs marché: Les bénéfices de MEDI ( 4.1% par an) devraient croître plus lentement que le marché Norwegian ( 9.4% par an).

Croissance élevée des bénéfices: Les bénéfices de MEDI devraient augmenter, mais pas de manière significative.

Chiffre d'affaires vs marché: Le chiffre d'affaires de MEDI ( 3.2% par an) devrait croître plus rapidement que le marché Norwegian ( 2.2% par an).

Croissance élevée des revenus: Le chiffre d'affaires de MEDI ( 3.2% par an) devrait croître plus lentement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de MEDI devrait être élevé dans 3 ans

Medistim Croissance future

Future contrôle des critères 2/6

Informations clés

Mises à jour récentes de la croissance future

Medistim ASA Just Missed Earnings - But Analysts Have Updated Their Models

Medistim ASA Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Medistim ASA Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Price target decreased by 10% to kr260

Consensus EPS estimates increase by 23%

Consensus forecasts updated

Recent updates

Medistim ASA Just Missed Earnings - But Analysts Have Updated Their Models

Third quarter 2024 earnings: Revenues miss analyst expectations

Now 20% overvalued after recent price rise

Medistim ASA Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Second quarter 2024 earnings: Revenues exceed analyst expectations

Now 6.6% overvalued

Now 26% overvalued after recent price rise

Now 20% overvalued

Medistim ASA Approves Dividend for the Year 2023, Payable on May 6, 2024

Medistim ASA Proposes Dividend

Medistim ASA Announces Board Changes

Medistim ASA Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Full year 2023 earnings released: EPS: kr5.68 (vs kr6.25 in FY 2022)

CEO & President recently bought kr1.9m worth of stock

Medistim ASA to Report Q1, 2024 Results on Apr 25, 2024

One Medistim ASA (OB:MEDI) Analyst Has Been Cutting Their Forecasts

Price target decreased by 10% to kr260

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Second quarter 2023 earnings released: EPS: kr1.80 (vs kr1.82 in 2Q 2022)

CEO & President recently sold kr10.0m worth of stock

Less than half of directors are independent

First quarter 2023 earnings released: EPS: kr1.41 (vs kr1.30 in 1Q 2022)

Upcoming dividend of kr4.50 per share at 1.6% yield

Independent Director recently bought kr301k worth of stock

Consensus EPS estimates increase by 23%

Full year 2022 earnings released: EPS: kr6.25 (vs kr4.99 in FY 2021)

Danske Bank A/S acquired a 5% stake in Medistim ASA.

Medistim ASA to Report First Half, 2023 Results on Aug 31, 2023

What Does Medistim ASA's (OB:MEDI) Share Price Indicate?

Third quarter 2022 earnings: Revenues miss analyst expectations

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Should You Be Adding Medistim (OB:MEDI) To Your Watchlist Today?

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus forecasts updated

Price target decreased to kr300

A Look At The Intrinsic Value Of Medistim ASA (OB:MEDI)

Investor sentiment improved over the past week

Consensus EPS estimates increase by 12%

First quarter 2022 earnings: EPS misses analyst expectations

Upcoming dividend of kr3.75 per share

Medistim (OB:MEDI) Is Increasing Its Dividend To kr3.75

Full year 2021 earnings: EPS and revenues miss analyst expectations

Investor sentiment improved over the past week

Medistim ASA Proposes Ordinary Dividend for 2021, Payable on 9 May 2022

Medistim (OB:MEDI) Is Paying Out A Larger Dividend Than Last Year

Investor sentiment deteriorated over the past week

Statutory Profit Doesn't Reflect How Good Medistim's (OB:MEDI) Earnings Are

Consensus EPS estimates fall by 20%

Medistim's (OB:MEDI) Shareholders Will Receive A Bigger Dividend Than Last Year

Independent Director recently bought kr104k worth of stock

Price target decreased to kr343

Medistim ASA Proposes Dividend

Full year 2021 earnings: EPS and revenues miss analyst expectations

Investor sentiment deteriorated over the past week

CEO & President recently bought kr4.4m worth of stock

Medistim (OB:MEDI) Is Reinvesting To Multiply In Value

Third quarter 2021 earnings released: EPS kr1.03 (vs kr0.79 in 3Q 2020)

Medistim (OB:MEDI) Might Become A Compounding Machine

Here's Why I Think Medistim (OB:MEDI) Might Deserve Your Attention Today

Second quarter 2021 earnings released: EPS kr1.88 (vs kr1.11 in 2Q 2020)

Chief Financial Officer recently sold kr6.6m worth of stock

Medistim ASA Announces the Launch of the Pay Per Procedure Functionality to Latest MiraQTM Platform in the US Market

Here's What Medistim's (OB:MEDI) Strong Returns On Capital Mean

First quarter 2021 earnings released: EPS kr1.20 (vs kr1.16 in 1Q 2020)

Medistim ASA Approves Dividend, Payable on May 7, 2021

Full year 2020 earnings released: EPS kr3.81 (vs kr3.87 in FY 2019)

Chairman recently sold kr179m worth of stock

Is Medistim ASA's(OB:MEDI) Recent Stock Performance Tethered To Its Strong Fundamentals?